Modeling of drug release from biodegradable triple-layered microparticles

Lee, Wei Li; Shi, Wenxiong; Low, Zheng Yang; Li, Shuzhou; Loo, Say Chye Joachim

2012

Lee, W. L., Shi, W., Low, Z. Y., Li, S., & Loo, S. C. J. (2012). Modeling of drug release from biodegradable triple-layered microparticles. *Journal of biomedical materials research part A*, 100A(12), 3353-3362.

<https://hdl.handle.net/10356/79834>

<https://doi.org/10.1002/jbm.a.34292>

© 2012 Wiley Periodicals, Inc. This is the author created version of a work that has been peer reviewed and accepted for publication by *Journal of biomedical materials research part A*, Wiley Periodicals, Inc. It incorporates referee's comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: <http://dx.doi.org/10.1002/jbm.a.34292>].

Downloaded on 26 Apr 2023 18:22:44 SGT

Journal of Biomedical Materials Research Journal

Copy of e-mail Notification

Journal of Biomedical Materials Research Published by John Wiley & Sons, Inc.

Dear Sir or Madam,

Please refer to this URL address

<http://115.111.50.156/jw/retrieval.aspx?pwd=5b80e3ff6d3b>

Login: your e-mail address

Password: 5b80e3ff6d3b

The site contains 1 file. You will need to have Adobe Acrobat Reader software to read these files. This is free software and is available for user downloading at <http://www.adobe.com/products/acrobat/readstep.html>.

This file contains:

Author Instructions Checklist

Adobe Acrobat Users - NOTES tool sheet

Reprint Order Information

Return fax form

A copy of your page proofs for your article

After printing the PDF file, please read the page proofs carefully and:

- 1) indicate changes or corrections in the margin of the page proofs;
- 2) answer all queries (footnotes A,B,C, etc.) on the last page of the PDF proof;
- 3) proofread any tables and equations carefully;
- 4) check that any Greek, especially "mu", has translated correctly.

Within 48 hours, please return corrections via e-mail or fax to the address given below:

Production Editor, JBMA

Cadmus Professional Communications

300 West Chestnut Street, Suite A

Ephrata, PA 17522-1987

U.S.A.

717-738-9478 or 717-738-9479 (fax)

jrnlpredjbma@cadmus.com

If you experience technical problems, please contact Balaji/Ramesh/SAM (e-mail: wileysupport@kwglobal.com,

Journal of Biomedical Materials Research Journal

Copy of e-mail Notification

phone: +91 (44) 4205-8888 (ext.217)). Be sure to include your article number.

If you have any questions regarding your article, please contact me.

PLEASE ALWAYS INCLUDE YOUR ARTICLE NO. (12-0303) WITH ALL CORRESPONDENCE.

This e-proof is to be used only for the purpose of returning corrections to the publisher.

Sincerely,

Production Editor, JBMA

Phone: 717 721 2641

Fax: 717-738-9478 or 717-738-9479 (fax)

E-mail: jrnprodjbma@cadmus.com

111 RIVER STREET, HOBOKEN, NJ 07030

*****IMMEDIATE RESPONSE REQUIRED*****

Your article will be published online via Wiley's EarlyView® service (wileyonlinelibrary.com) shortly after receipt of corrections. Articles posted online in EarlyView® are peer-reviewed, copyedited, author corrected, and fully citable via the article DOI (for further information, visit www.doi.org). EarlyView® means you benefit from the best of two worlds--fast online availability as well as traditional, issue-based archiving.

☐ **READ PROOFS CAREFULLY**

- This will be your only chance to review these proofs. Please note that once your corrected article is posted online, it is considered legally published, and cannot be removed from the Web site for further corrections.
- Please note that the volume and page numbers shown on the proofs are for position only.

☐ **ANSWER ALL QUERIES ON PROOFS**

- Please annotate all corrections and remember to respond to all author queries at the back of your page proofs.

☐ **CHECK FIGURES AND TABLES CAREFULLY**

- Check size, numbering, and orientation of figures.
- All images in the PDF are downsampled (reduced to lower resolution and file size) to facilitate Internet delivery. These images will appear at higher resolution and sharpness in the printed article.
- Review figure legends to ensure that they are complete.
- Check all tables. Review layout, title, and footnotes.

RETURN

☐ **CORRECTED PROOFS**

☐ **Other forms as needed**

**The preferred method to return corrected proofs is to return the annotated PDF to
jrnprodjbma@cadmus.com.**

If this is not possible you may fax to 717-738-9478 or 717-738-9479

RETURN ALL RELEVANT ITEMS WITHIN 48 HOURS OF RECEIPT

USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION

Required software to e-Annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 7.0 or above). (Note that this document uses screenshots from Adobe Reader X)
The latest version of Acrobat Reader can be downloaded for free at: <http://get.adobe.com/uk/reader/>

Once you have Acrobat Reader open on your computer, click on the [Comment](#) tab at the right of the toolbar:

This will open up a panel down the right side of the document. The majority of tools you will use for annotating your proof will be in the [Annotations](#) section, pictured opposite. We've picked out some of these tools below:

1. [Replace \(Ins\)](#) Tool – for replacing text.

Strikes a line through text and opens up a text box where replacement text can be entered.

How to use it

- Highlight a word or sentence.
- Click on the [Replace \(Ins\)](#) icon in the Annotations section.
- Type the replacement text into the blue box that appears.

2. [Strikethrough \(Del\)](#) Tool – for deleting text.

Strikes a red line through text that is to be deleted.

How to use it

- Highlight a word or sentence.
- Click on the [Strikethrough \(Del\)](#) icon in the Annotations section.

3. [Add note to text](#) Tool – for highlighting a section to be changed to bold or italic.

Highlights text in yellow and opens up a text box where comments can be entered.

How to use it

- Highlight the relevant section of text.
- Click on the [Add note to text](#) icon in the Annotations section.
- Type instruction on what should be changed regarding the text into the yellow box that appears.

4. [Add sticky note](#) Tool – for making notes at specific points in the text.

Marks a point in the proof where a comment needs to be highlighted.

How to use it

- Click on the [Add sticky note](#) icon in the Annotations section.
- Click at the point in the proof where the comment should be inserted.
- Type the comment into the yellow box that appears.

USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION

5. **Attach File** Tool – for inserting large amounts of text or replacement figures.

Inserts an icon linking to the attached file in the appropriate place in the text.

How to use it

- Click on the **Attach File** icon in the Annotations section.
- Click on the proof to where you'd like the attached file to be linked.
- Select the file to be attached from your computer or network.
- Select the colour and type of icon that will appear in the proof. Click OK.

6. **Add stamp** Tool – for approving a proof if no corrections are required.

Inserts a selected stamp onto an appropriate place in the proof.

How to use it

- Click on the **Add stamp** icon in the Annotations section.
- Select the stamp you want to use. (The **Approved** stamp is usually available directly in the menu that appears).
- Click on the proof where you'd like the stamp to appear. (Where a proof is to be approved as it is, this would normally be on the first page).

of the business cycle, starting with the
on perfect competition, constant returns
production. In this environment goods
extra profits and the structure of market
he model for the New-Keynesian model
etermined by the model. The New-Keynesian
otaki (1987), has introduced product
general equilibrium models with nominal
ad and supply shocks. Most of this literature

APPROVED

7. **Drawing Markups** Tools – for drawing shapes, lines and freeform annotations on proofs and commenting on these marks.

Allows shapes, lines and freeform annotations to be drawn on proofs and for comment to be made on these marks..

How to use it

- Click on one of the shapes in the **Drawing Markups** section.
- Click on the proof at the relevant point and draw the selected shape with the cursor.
- To add a comment to the drawn shape, move the cursor over the shape until an arrowhead appears.
- Double click on the shape and type any text in the red box that appears.

For further information on how to annotate proofs, click on the **Help** menu to reveal a list of further options:

Additional reprint purchases

Should you wish to purchase additional copies of your article, please click on the link and follow the instructions provided:

<https://caesar.sheridan.com/reprints/redir.php?pub=10089&acro=JBMA>

Corresponding authors are invited to inform their co-authors of the reprint options available.

Please note that regardless of the form in which they are acquired, reprints should not be resold, nor further disseminated in electronic form, nor deployed in part or in whole in any marketing, promotional or educational contexts without authorization from Wiley. Permissions requests should be directed to mail to: permissionsus@wiley.com

For information about 'Pay-Per-View and Article Select' click on the following link: wileyonlinelibrary.com/aboutus/ppv-articleselect.html

COLOR REPRODUCTION IN YOUR ARTICLE

Color figures were included with the final manuscript files that we received for your article. Because of the high cost of color printing, we can only print figures in color if authors cover the expense.

Please indicate if you would like your figures to be printed in color or black and white. Color images will be reproduced online in *Wiley Online Library* at no charge, whether or not you opt for color printing.

You will be invoiced for color charges once the article has been published in print.

Failure to return this form with your article proofs will delay the publication of your article.

Journal of Biomedical Materials Research			
JOURNAL			
MS. NO.	JBMR-A-12-0303	NO. OF COLOR PAGES	5
TITLE OF MANUSCRIPT			
AUTHOR(S)	Wei Li Lee, Wen-Xiong Shi, Zheng Yang Low, Shuzhou Li, Say Chye Joachim Loo		

Color Pages	1 Figure per Page	2 Figures per Page	3 Figures per Page	4 Figures per Page	5 Figures per Page	6 Figures per Page
1	850	1000	1150	1300	1450	1600
2	1700	1850	2000	2150	2300	2450
3	2550	2700	2850	3000	3150	3300
4	3400	3550	3700	3850	4000	4150
5	4250	4400	4550	4700	4850	5000
6	5100	5250	5400	5550	5700	5850

Please contact the Production Editor at jrnlpordjbma@cadmus.com for a quote if you have more than 6 pages of color

☐ Please print my figures in black and white

☐ Please print my figures in color \$ _____

***International orders must be paid in currency and drawn on a U.S. bank*

BILL TO: Name _____ Institution _____ Address _____ _____ _____	Purchase Order No. _____ Phone _____ Fax _____ E-mail _____
---	---

Modeling of drug release from biodegradable triple-layered microparticles

AQ2

Wei Li Lee, Wenxiong Shi, Zheng Yang Low, Shuzhou Li, Say Chye Joachim Loo

School of Materials Science and Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore

Received 9 April 2012; accepted 22 May 2012

Published online 00 Month 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/jbm.a.34292

Abstract: Numerous models that predict drug release from nonerodible reservoir-membrane sphere systems have been presented. Most of these models cater only to a phase of drug release from a constant reservoir. All these models, however, are not applicable to drug release from biodegradable triple-layered microparticle system, in which the drug-loaded core (reservoir) is surrounded by nondrug holding outer layers (membrane). In this article, a mathematical model was developed for ibuprofen release from degradable triple-layered microparticles made of poly(D,L-lactide-co-glycolide, 50:50) (PLGA), poly(L-lactide) (PLLA), and poly(ethylene-co-vinyl acetate, 40 wt % vinyl acetate) (EVA), where ibuprofen was localized within the nonconstant reservoir (EVA core). The model postulated that the drug release through the bulk-degrading PLLA and PLGA layers consisted

of two mechanisms: simple diffusional release followed by a degradation-controlled release through a rate-limiting membrane. The proposed model showed very good match with the experimental data of release from microparticles of various layer thicknesses and particle sizes. The underlying drug release mechanisms are dictated by three parameters determined by the model, including constant characteristic of diffusion, end time point of simple diffusion-controlled release and partition coefficient of drug. The presented model is effective for understanding the drug release mechanisms and for the design of this type of dosage form. © 2012 Wiley Periodicals, Inc. *J Biomed Mater Res Part A*: 00A:000–000, 2012.

Key Words: biodegradable polymers, drug delivery, poly(lactic acid), poly(DL-lactide-co-glycolide), release model

How to cite this article: Lee WL, Shi W, Low ZY, Li S, Loo SCJ. 2012. Modeling of drug release from biodegradable triple-layered microparticles. *J Biomed Mater Res Part A* 2012;00A:000–000.

INTRODUCTION

Biodegradable polymeric microparticles have received significant interest for applications in drug delivery over the past decade.^{1,2} However, single-layered polymeric microparticles have several inherent problems, including burst release of drugs and the inability to achieve constant drug release. Subsequently, this led to the development of double-layered and triple-layered microparticles, whereby the outer layers function as rate-limiting membranes to better control drug release.^{3–9}

Our group previously reported on the fabrication of biodegradable triple-layered microparticles composed of poly(D,L-lactide-co-glycolide, 50:50) (PLGA), poly(L-lactide) (PLLA), and poly(ethylene-co-vinyl acetate, 40 wt % vinyl acetate) (EVA) (shell to core).¹⁰ This triple-layered microparticle system can be envisioned as a membrane-based reservoir system with drug localized in the core. Ibuprofen (a model hydrophobic drug) was preferentially localized in the EVA core due to the hydrophobic interaction between hydrophobic ethylene chains in EVA and drug molecules.

Rubbery EVA is permeable to ibuprofen, which would not face much difficulty to dissolve in and diffuse through EVA, thus forming a dissolved drug reservoir system. The non-drug holding outer layers of PLGA and PLLA can serve as the rate-controlling layers for the release of ibuprofen. It has been shown that by changing particle parameters, that is layer thickness, particle size, and so forth, the drug release kinetics and profiles can be altered,^{6,7} thus allowing for particles to be designed to suit a certain drug delivery application. For instance, multilayered microparticles could be envisioned to provide pulsatile drug release kinetics for vaccination. It would also appear that the sustained delivery of radiosensitizers and/or anticancer drugs by multilayered microparticles could be appropriate for cancer therapy. Furthermore, multilayered particulate system could function as a tissue scaffold and deliver bioactive molecules to cells.

Mathematical models have garnered much interest in the development of controlled release systems in the past few decades.^{11,12} Several physicochemical factors controlling drug release from polymeric dosage forms include water

Correspondence to: S. Li; e-mail: liz@ntu.edu.sg or S. Chye J. Loo; e-mail: joachimloo@ntu.edu.sg

Contract grant sponsor: National Medical Research Council (NMRC); contract grant number: EDG/0062/2009

Contract grant sponsor: Agency for Science, Technology & Research (A*STAR: SERC); contract grant number: 102 129 0098

Contract grant sponsor: Nanyang Institute of Technology in Health and Medicine (NITHM)

and drug diffusion, polymer swelling, drug and polymer dissolution, polymer degradation/erosion and osmotic effects.^{13,14} More notably, a review of the mathematical models for surface-eroding and bulk-eroding degradable systems has been conducted by Siepmann et al.¹⁵ As the polymers used in this work, polyesters, undergo bulk erosion, the majority of these drug release models are based on the Higuchi model with the implementation of time-dependent diffusion coefficient.^{16,17} However, these models are obtained only for monophasic drug release patterns when diffusion becomes the rate-limiting step throughout the release period. These models will not be applicable for biphasic drug release profiles. Apart from matrix systems, numerous models that predict the drug release pattern of a nonerodible reservoir-membrane system with varying coating thickness and device dimensions (e.g. slab, cylinder, and sphere) have been reported in the literature.^{18–20} Nevertheless, none of these models are applicable to bulk-eroding membrane-based reservoir systems. It is known that polymer chains mobility increases with decreasing molecular weight as a result of degradation, thus allowing drug molecules to diffuse more quickly from one cavity to another.^{17,21} In view of this, a more accurate predictive scenario would be to replace the constant diffusion coefficient (D_0) with a time-dependent diffusion coefficient (D_t).^{16,22} At the same time, because the drug content in the delivery system is finite, one must consider that the reservoir drug concentration becomes nonconstant as drugs are dissolved. However, a mathematical model to illustrate the entire course of drug release from a non-constant reservoir with a degrading membrane has yet to be established.

In view of these, the aim of this study was to model and quantitatively describe the biphasic drug release profiles of biodegradable triple-layered microparticles of different layer thicknesses and particle sizes. This model would provide important insights concerning the identification of the dominant mass transport phenomena and the underlying drug release mechanisms from such multilayered particulate system. It can also be applied to quantitatively describe the effects of the structural composition and device geometry on the resulting drug release kinetics. Based on the dependency, this model would be applicable to describe a biphasic release pattern, usually observed from other multilayered particulate systems with the drug encapsulated within the core.^{3,4,7,23} This knowledge would thus facilitate the device design with desirable drug release profiles.

MATERIALS AND METHODS

Materials

PLLA (intrinsic viscosity/IV: 2.38, Bio Invigor), poly(D,L-lactic-co-glycolic acid, 50:50) (PLGA, IV: 1.18, Bio Invigor), EVA (molecular weight/MW: 42 kDa, Aldrich), and poly(vinyl alcohol) (PVA, MW: 30–70 kDa, Sigma-Aldrich) were used without further purification. The model drug, ibuprofen, was purchased from Sigma-Aldrich and used as received. Dichloromethane (DCM), tetrahydrofuran (THF), and chloro-

form from Tedia Company Inc. were of High-Performance Liquid Chromatography grade. Phosphate buffered saline (PBS) solution with a pH 7.4 was purchased from OHME, Singapore.

Fabrication of microparticles

The (oil-in-water) emulsion solvent evaporation method was used to prepare the triple-layered PLGA/PLLA/EVA microparticles.^{10,24} Polymer solution at 7.5% (w/v) was prepared with a mixture of PLGA (0.2 g), PLLA (0.1 g), EVA (0.05 g), and ibuprofen (5%, w/w) dissolved in DCM. Subsequently, the resultant polymer solution was initially ultrasonicated for 1 min before adding to an aqueous solution containing PVA (0.5%, w/v), with an oil-to-water ratio of 0.013. After which, the emulsification was conducted at 400 rpm using an overhead stirrer (Calframo BDC1850-220) at room temperature (25°C). The evaporation of volatile DCM resulted in the formation of triple-layered PLGA/PLLA/EVA 4:2:1 microparticles. To retrieve these microparticles, the sample was centrifuged, rinsed with deionized water, lyophilized, and subsequently stored in desiccators for further characterization.

The same method was employed to produce triple-layered microparticles of different layer thicknesses (PLGA/PLLA/EVA 10:2:1 and 10:5:1).¹⁰ Ibuprofen-loaded triple-layered PLGA/PLLA/EVA 8:2:1 microparticles of various sizes were prepared in the similar manner as mentioned above. To obtain triple-layered microparticles of various size ranges, the poly-dispersed microparticles were sieved with various test sieves with pore size of 150 μm , 106 μm , 75 μm , 53 μm , and 38 μm (Cole-Parmer® U.S.A. Standard Test Sieve) for 30 min.¹⁷

Characterization

Morphological study. The surface and internal morphologies of microparticles were analyzed using a JEOL JSM-6360A scanning electron microscope (SEM) at an operating voltage of 5 kV. The samples were initially mounted onto metal stubs and cross-sectioned with a razor blade. After which, samples were coated with gold using a sputter coater model SPI-Module. For every batch of samples, 10 microparticles were randomly chosen to be viewed under the SEM. Only one representative SEM image is shown as a consistent morphology was observed for all 10 particles within each batch. Particle size (in diameter) and layer dimension were measured using the ImageJ software.

Determination of actual drug loading. The amount of ibuprofen loaded was determined using Thermal Gravimetric Analysis (TGA Q500 V6.5 Build 196). Approximately 10 mg of the ibuprofen-loaded microparticles was placed on a platinum pan. Ibuprofen is known to decompose at 160°C, which is lower than for the polymers (~300°C).⁷ Hence, the measurements (in triplicate) were performed at rate of 10°C min⁻¹ from initial room temperature to 160°C under nitrogen flow of 60 mL min⁻¹,

followed by isothermal heating at 160°C for 60 min, and finally ramping to 500°C.

***In vitro* hydrolytic degradation study**

Forty milligrams of microparticles were placed in vials containing 30 mL of PBS solution (pH 7.4) in triplicate, and maintained at 37°C in a shaking incubator. The pH of the solution was monitored over time to ensure a stable pH of 7.4. Subsequently, at predetermined time intervals, the microparticles were removed from vials.

Mass loss. The samples were vacuum-dried and the dry mass (m_d) was recorded. Mass loss was calculated according to the difference between the initial mass (m_o) of the sample and m_d , and divided by the initial mass.

Molecular weight analysis. Agilent 1100 Series LC System was used to determine the molecular weight of each of the samples. The size-exclusion chromatography (SEC) experiments were performed at 30°C with chloroform as solvent, using a reflective index detector, and the flow rate used was 1 mL min⁻¹. Eight milligrams of triple-layered microparticles were initially immersed in 1 mL of THF to dissolve the PLGA and EVA constituent. PLLA remnants were separated from the polymer solution thorough centrifugation. The volatile solvent in the polymer solution containing PLGA and EVA was allowed for evaporation in air at room temperature for 48 h. After which, PLGA, EVA, and PLLA remnants were dried in an oven at 40°C for a week. Finally, PLGA/EVA mixture and PLLA dissolved separately in 1 mL chloroform were tested with SEC.

Drug release study. Ibuprofen-loaded microparticles (5 mg) were accurately weighed in triplicate and placed in vials containing 5 mL of PBS (pH 7.4), followed by incubation at 37°C. At predetermined time intervals, 1 mL of PBS medium from each sample was extracted and the concentration of ibuprofen released in PBS medium was determined using UV-Vis spectrometer (UV-2501, Shimadzu) at 220 nm. The removed PBS was replaced with fresh PBS solution. Drug release data from different sets of particles were evaluated by unpaired Student's *t*-test and the one-way analysis of variance analysis coupled with Tukey's multiple comparison tests. Differences were considered statistically significant when $p \leq 0.05$.

THEORETICAL METHODS

In the modeling analysis, drug release from the triple-layered PLGA/PLLA/EVA (shell to core) microparticles with ibuprofen localized in the EVA core follows a three-step sequential process:

- (1) water penetration into the microparticles;
- (2) drug release to the surrounding release medium by simple diffusion process;
- (3) a membrane-reservoir system: drug release is controlled by degradation where drug is diffusing out through a rate-limiting membrane that is undergoing degradation.

Several assumptions were considered in the modeling analysis of drug release:

- (1) The surrounding water bath is perfectly stirred.
- (2) Sink conditions. At the particle surface, drug concentration is zero when mass transfer limitation does not exist and the volume of surrounding medium is large.²⁵
- (3) Water penetration and drug dissolution in the core are much more rapid than the drug diffusion through the outer layers. The presence of relatively more hydrophilic PLGA shell arising from its fully amorphous structure results in appreciable water uptake. The EVA core has a very low glass transition temperature (−40°C). A highly flexible rubbery state of EVA chains at 37°C (test condition for drug release) creates sufficient free volume for drug dissolution.
- (4) No initial burst (i.e. no substantial amount of drug in the coating layer).
- (5) The diffusion of drug molecules is Fickian.
- (6) Diffusion coefficient and partition coefficient of drug are independent of its concentration.
- (7) Polymers are completely immiscible and phase separated.

As reported previously in the literature, before drug is released through a rate-limiting membrane in the membrane-reservoir system, a slow initial drug release is often observed when little or no drug is in the coating layer.¹⁹ Lag time is a finite time interval required to establish a steady state of drug concentration gradient across the membrane with easy drug partitioning, during which the drug diffuses through the membrane and is released towards the steady state value. As such, a temporal idiosyncrasy of initial slow release phase from a membrane-reservoir dosage form was included in the model. This suggests that, in the investigated system, the drug was first released by simple diffusion (stage 1).^{3,26} Drug release was subsequently controlled by polymer degradation (stage 2) where the formation of pores and significant decrease in molecular weight influence drug release more substantially than diffusion. During this stage, drug was released through a rate-limiting outer layer (membrane) where a concentration profile of the drug in the membrane had been established (stage 2).

Herein, the Fick's second law of diffusion under non-steady state condition for drug release from microsphere is utilized for stage 2, as shown in Eq. (1).

$$\partial C / \partial t = (1/r^2) \{ \partial / \partial r [Dr^2 (\partial C / \partial r)] \} \quad (1)$$

D is the diffusion coefficient of drug, C is the drug concentration in the polymer matrix, t is time, and r is the position in the radial direction. In a membrane-reservoir system, drug located in the reservoir (core) has to diffuse through a membrane layer with thickness of $R - R_i$, where R and R_i are the outer and inner radii, respectively.¹⁸ Next, the boundary conditions were employed. The drug distribution within the shell ($R_i \leq r \leq R$) is obtained by solving Fick's second law of diffusion, where the reservoir concentration

($C_r = C_i/K$) is kept at the surface $r = R_i$. K is the drug partition coefficient at the interface between the reservoir and shell matrix. The concentration of drug at $r = R$ is zero. By considering a sufficient long time period, a steady state of drug concentration gradient across the membrane would be achieved, thus resulting in a constant diffusion rate of drug released from the reservoir. The solution to this diffusion problem is shown below [Eq. (2)]:

$$dM/dt = 4\pi[RR_i/(R - R_i)]DC_i \quad (2)$$

This mathematical model [Eq. (2)] was combined with an equation considering polymer membrane degradation. According to Charlier et al.,²² time-dependent diffusion coefficient, D_v is expressed as $D_t = D_o \exp(k_{deg}t)$ due to an exponential decay of the molecular weight (pseudo-first-order degradation kinetics), where k_{deg} is the degradation rate constant, D_o is the diffusion coefficient of drug in the nondegraded polymer ($t = 0$), and t is time. As such, Eq. (2) is modified to be as below [Eq. (3)]:

$$dM/dt = 4\pi[RR_i/(R - R_i)]D_o \exp(k_{deg}t)C_i \quad (3)$$

In contrast, because the dissolved drug content (below the drug solubility limit in the polymer matrix) in the system is finite, it is to be noted that the reservoir drug concentration becomes nonconstant upon drug release and is governed by the drug release rates. C_r has to be determined as a function of time according to mass balance using the following equation [Eq. (4)], where V is the volume of the core (i.e. reservoir):

$$-V(dC_r/dt) = dM/dt \quad (4)$$

$$-V(dC_r/dt) = 4\pi[RR_i/(R - R_i)]D_o \exp(k_{deg}t)C_rK \quad (5)$$

The left-hand side of Eq. (5) is the decreased amount of drug located in the core and the term on the right-hand side represents the amount of drug released into the surrounding medium. The variable concentration C_r can then be determined, as shown in Eq. (6):

$$C_r = C_o \exp\{(K/V)(4\pi)[RR_i/(R - R_i)]D_o(1/k_{deg}) \times [\exp(k_{deg}t) - \exp(k_{deg}t_a)]\} \quad (6)$$

t_a is the end of simple diffusion-controlled release (stage 1) and, at the same time, the commencement of degrading membrane-controlled release (stage 2), and C_o is the drug concentration in the core at time t_a .

The fraction of drug release from the triple-layered microparticles at the stage 2 only is

$$(M_t/M_\infty)_{\text{stage 2}} = (V/M_\infty)(C_o - C_r) = [V/(C_o V)](C_o - C_r) = 1 - C_r/C_o$$

and thus

$$(M_t/M_\infty)_{\text{stage 2}} = 1 - \exp\{(K/V)(4\pi)[RR_i/(R - R_i)] \times D_o(1/k_{deg})[\exp(k_{deg}t) - \exp(k_{deg}t_a)]\} \quad (7)$$

The complete analytical solution for the entire course of drug release is described below:

$$M_t/M_\infty = at^{0.43}, \text{ at } t \leq t_a \quad (8)$$

$$M_t/M_\infty = at_a^{0.43} + (1 - at_a^{0.43})[1 - \exp\{-(K/V)(4\pi) \times [RR_i/(R - R_i)]D_o(1/k_{deg})[\exp(k_{deg}t) - \exp(k_{deg}t_a)]\}], \text{ at } t > t_a \quad (9)$$

Eq. (8) is used for the period of $t \leq t_a$, which describes the simple diffusion-controlled release at stage 1,^{3,27,28} where a is the constant characteristic of diffusion. It is well known that a power law could approximate the Fickian diffusion from the sphere geometry, with an exponent of 0.43.¹² According to the analyses above, both modes of drug release are combined in the proposed model for the period of $t > t_a$. The cumulative fraction of drug release from triple-layered microparticles for the period of $t > t_a$ is described as the sum of drug release due to a simple diffusion-controlled release (first term on the right-hand side) plus the degrading membrane-controlled release (second term on the right-hand side), as described in Eq. (9).

MATLAB®, a programming software (Mathwork, 2007a), was then used to fit the proposed model, Eqs. (8) and (9), to the experimental data of drug release from the triple-layered microparticles with different layer thicknesses and various sizes. The correlation coefficients (R^2) between the experimental and theoretical results were compared to obtain a precise theoretical description for the drug release model.

RESULTS

Particles of different layer thicknesses

The diffusion coefficients of drug, D_o , in the nondegraded PLLA and PLGA at time = 0 were determined by fitting $D = D_o \exp(k_{deg}t)$ and Eq. (10) to sets of experimentally measured ibuprofen release rates of PLGA- and PLLA-based neat microparticles.

$$M_t/M_\infty = 1 - 6/\pi^2 \sum_{n=1}^{\infty} (1/n^2) \exp[-n^2\pi^2 Dt/R^2] \quad (10)$$

Eq. (10) describes the dissolved drug system where initial drug loading is below the drug saturation limit in the polymer matrix; therefore the drug is dissolved in the polymer matrix.²⁹ M_t/M_∞ is the cumulative fraction of drug release at time t , and R is the radius of the microparticles. The value of k_{deg} was obtained by fitting the pseudo first-order equation describing an exponential decrease in the molecular weights of polymers with degradation time ($MW = MW_o \exp(-k_{deg}t)$) into the experimental SEC results,^{22,30} where MW_o is the initial polymer molecular weight before immersion in the release medium. The apparent degradation rate constants, k_{deg} , of polymers with a good agreement ($R^2 > 0.9$ in all cases) were obtained. The k_{deg} value of PLLA and PLGA were 0.0566 day⁻¹ and 0.2655 day⁻¹, respectively. The diffusion coefficients of ibuprofen, D_o , in the

FIGURE 1. Plot of ratios of diffusion coefficient of ibuprofen in PLGA to that of PLLA over the degradation time.

nondegraded PLLA and PLGA were found to be $4.1829 \times 10^{-12} \text{ cm}^2/\text{s}$ and $6.59 \times 10^{-10} \text{ cm}^2/\text{s}$, respectively. The diffusion coefficient values obtained are in agreement with those measured by other groups for similar system.^{21,31}

F1 Figure 1 plots the ratio of diffusion coefficient of drug in PLGA to that in PLLA over the degradation time for the tri-

FIGURE 2. (a) Mass loss of the degrading triple-layered PLGA/PLLA/EVA 4:2:1 microparticles as a function of incubation time. (b) SEM image of the degrading ibuprofen-loaded triple-layered PLGA/PLLA/EVA 4:2:1 microparticles after 15 days *in vitro*.

FIGURE 3. Model and experimental data matching of ibuprofen release from triple-layered microparticles. Polymer mass ratios PLGA/PLLA/EVA (a) 4:2:1, (b) 10:2:1, and (c) 10:5:1. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

ple-layered PLGA/PLLA/EVA 4:2:1 microparticles. After 10 days *in vitro*, the diffusion coefficient of drug in PLGA is about 2000 times higher than that in PLLA. As can be seen in Figure 2, massive mass loss causing the formation of pores in PLGA shell was observed for the triple-layered PLGA/PLLA/EVA 4:2:1 microparticles after 10 days *in vitro*. The porosity of the PLGA shell would allow for the direct access to the release medium to the inner layers.³² As such,

FIGURE 4. Plot of cumulative ibuprofen release from triple-layered microparticles with various polymer mass ratios (PLGA/PLLA/EVA) versus time^{0.43}. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

the partitioning of drug from PLLA middle layer into PLGA shell and the release through the PLGA shell would be rapid. These results imply that the rate-limiting step would predominantly occur in PLLA due to its high glass transition temperature, increased crystallinity and slow degradation rate.⁵ The effect of PLGA shell on the drug release rates during stage 2 is thus omitted from the release models because only the rate-limiting step of PLLA layer determines the release rate and is reflected in the models.

The actual drug loading of all samples were at $4 \pm 0.5\%$ (w/w). Figure 3 shows the plots of the model and experimental release profiles with good correlation coefficients ($R^2 \approx 0.99$). From Figure 3, biphasic drug release patterns were observed for all triple-layered microparticles with different thicknesses but with comparable particle sizes. As highlighted in the theoretical model, ibuprofen was first released through a simple diffusional process, and subsequently released through a rate-limiting outer layer of PLLA that was undergoing hydrolytic degradation. The plot of the initial drug release data for cumulative release percentage versus time^{0.43} shows a linear profile ($R^2 > 0.9$ at

all cases) (Fig. 4), suggesting the simple-diffusion controlled release of ibuprofen that had diffused into the outer layer upon water ingress during the early release period.^{3,12,26–28} According to Raghuvanshi et al.,³³ the initial stage of degradation involves random chain scission with no appreciable mass loss, as observed from Figure 2(a). Drug release was therefore controlled by simple diffusion during this initial stage of degradation.

Table I lists the values of all known parameters and parameters determined by the model for the triple-layered microparticles of different layer thicknesses but with comparable particle sizes and actual drug loadings of $4 \pm 0.5\%$ (w/w). The constant characteristic of diffusion of triple-layered PLGA/PLGA/EVA 4:2:1 microparticles was found to be the highest. In contrast, drug diffusion of the microparticles with the mass ratios of PLGA/PLLA/EVA 10:2:1 seems to be slower than 10:5:1 microparticles.

Partition coefficient is the ratio of concentrations of the drug in the two phases (i.e. PLLA and EVA). It was observed that the partition coefficient of drug increased with increasing PLLA degradation rates, as shown in Table I. In contrast, the longest end time of stage 1 (t_a), at day 18, was observed for the triple-layered PLGA/PLLA/EVA 10:2:1 microparticles, whereas relatively similar t_a (i.e. 8.9 and 11 days) were observed for 4:2:1 and 10:5:1 microparticles.

Particles of various sizes. Figure 5 shows the cumulative ibuprofen release versus time for five different particle size ranges. The actual drug loading of all samples were approximately 4% (w/w). Clearly, it was observed that each microparticle system of different sizes exhibited a different release pattern of ibuprofen in which a trend of an increasing drug release rate with decreasing particle size was shown.

The same approach was utilized to model the drug release profiles of triple-layered PLGA/PLLA/EVA 8:2:1 microparticles, and to determine the model parameters of ibuprofen release from triple-layered PLGA/PLLA/EVA 8:2:1 microparticles of various sizes, as listed in Table II. As

TABLE I. Model Parameters of Ibuprofen Release from Triple-Layered PLGA/PLLA/EVA Microparticles with Different Layer Thicknesses

Parameters	Description	Unit	4:2:1	10:2:1	10:5:1
<i>Known parameters</i>					
R_{particle}	Radius of particle (PLGA + PLLA + EVA)	μm	135.2	134.7	141.5
R	Second inner radius (PLLA + EVA)	μm	113.5	76.8	108.8
R_i	Innermost radius (EVA)	μm	77	51.1	57.6
$R_{\text{particle}} - R$	PLGA layer thickness	μm	21.7	57.9	32.7
$R - R_i$	PLLA layer thickness	μm	36.5	25.7	51.2
k_{deg}	Degradation rate constant of PLLA	day^{-1}	0.0357	0.0089	0.0330
D_o	Drug diffusion coefficient in PLLA phase	cm^2/s		4.1829×10^{-12}	
<i>Parameters determined by the model</i>					
a	Constant characteristic of diffusion	$\text{s}^{-0.43}$	0.08097	0.04211	0.04867
t_a	End of simple diffusion-controlled release (stage 1)	days	8.9	18	11
K	Partition coefficient of drug, [PLLA]/[EVA]	–	0.547	0.139	0.336
<i>Goodness of fit</i>					
R^2	Correlation factor	–	0.98440	0.99552	0.99006

FIGURE 5. Release profiles of ibuprofen from triple-layered PLGA/PLLA/EVA microparticles of various sizes (in diameter). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

As shown in Figure 6, good agreement between model and experimentally measured data for the microparticles of various size ranges was obtained ($R^2 > 0.99$). The constant characteristics of diffusion were observed to increase with decreasing particle size. Interestingly, it was found that the end of stage 1 for all the investigated size ranges was at around day 8. Similar to the modeling result of the particles of different layer thicknesses, the partition coefficient of drug increased with increasing degradation rate of the PLLA rate-limiting layer.

DISCUSSION

Particles of different layer thicknesses

Three parameters, including constant characteristic of diffusion, end time point of simple diffusion-controlled release and partition coefficient of drug, could be determined by the model. The highest constant characteristic of diffusion for the triple-layered PLGA/PLLA/EVA 4:2:1 microparticles indicates the fastest rate of diffusional release for the thinnest outer layers (the shortest diffusion length). In contrast, the drug diffusion rate of PLGA/PLLA/EVA 10:2:1 microparticles was slower than 10:5:1 microparticles, partly because of the slower degradation of PLLA layer in 10:2:1 microparticles, as shown by the degradation rate constants in Table

I. More open structure resulting from a higher content (77 wt %) of fully amorphous PLGA would allow more basic ions (from the phosphate buffer) to diffuse into the PLLA middle layer of triple-layered PLGA/PLLA/EVA 10:2:1 microparticles, neutralizing the generated acidic oligomers,²¹ when compared with lower PLGA content of 62.5 wt % for 10:5:1 microparticles. In addition, thinner PLLA layer would reduce the occurrence of autocatalytic effects, resulting in a slower degradation rate of PLLA in 10:2:1 microparticles.³⁴

The molecular weights of degraded PLLA in 4:2:1, 10:2:1, and 10:5:1 microparticles at day t_a were 98 kDa, 180 kDa, and 101 kDa, respectively. This implied that the extent of degradation at which the mass transport phenomena switching from simple diffusion to diffusion through the eroding rate-limiting layer was varied with particles of different layer thicknesses (polymer mass ratios). Therefore, this switch of mass transport phenomena is dependent on the extent of degradation and layer dimensions. When the polymer layer has undergone a certain extent of degradation, shorter t_a would be obtained for the thinner layer due to its decreased diffusion pathway length. For triple-layered PLGA/PLLA/EVA 10:2:1 microparticles (with the thinnest PLLA layer), the longer time (18 days) required to establish a drug concentration gradient across the membrane with easy drug partitioning could be attributed to its significantly slower degradation of PLLA layer ($k_{deg} = 0.0089 \text{ day}^{-1}$), when compared with 0.0357 day^{-1} and 0.0330 day^{-1} for 4:2:1 and 10:5:1 microparticles, respectively. This slow degradation rate resulted in a denser and less permeable matrix structure, and prolonged the simple diffusional release.

In the early stage of degradation, PLLA is a relatively hydrophobic and highly glassy polymer. Therefore, very limited free volume was available for ibuprofen to partition into the PLLA layer. This drug partitioning is dependent on polymer degradation, causing chain scission and polymer relaxation to produce a more "open" network. The creation of more free volume as a result of the significantly decreased molecular weight (degradation) facilitates the drug partitioning and promotes further release. Therefore, the partition coefficient of drug was observed to increase with increasing PLLA degradation rates.

TABLE II. Parameters of Ibuprofen Release from Triple-Layered PLGA/PLLA/EVA 8:2:1 Microparticles of Various Sizes

Parameters	Description	Unit	38–10 μm	53–38 μm	75–53 μm	106–75 μm	150–106 μm
<i>Known parameters</i>							
R_{particle}	Radius of particle (PLGA + PLLA + EVA)	μm	10	20.8	28.1	39.7	68.65
R	Second inner radius (PLLA + EVA)	μm	7.4	15.5	20.9	29.5	51.0
R_i	Innermost radius (EVA)	μm	5.1	10.7	14.4	20.3	35.2
k_{deg}	Degradation rate constant of PLLA	day ^{−1}	0.0237	0.0332	0.0352	0.0395	0.0418
D_o	Drug diffusion coefficient in PLLA phase	cm ² /s	4.1829 × 10 ^{−12}				
<i>Parameters determined by the model</i>							
a	Constant characteristic of diffusion	s ^{−0.43}	0.30013	0.27062	0.25084	0.20906	0.14659
t_a	End of simple diffusion-controlled release (stage 1)	days	8	8	8	8.1	7.6
K	Partition coefficient of drug, [PLLA]/[EVA]	–	0.009	0.013	0.052	0.103	0.130
<i>Goodness of fit</i>							
R^2	Correlation factor	–	0.9955	0.99693	0.99765	0.99791	0.99834

FIGURE 6. Model and experimental data matching of ibuprofen release from triple-layered PLGA/PLLA/EVA microparticles. (a) 38–10 μm , (b) 53–38 μm , (c) 75–53 μm , (d) 106–75 μm , and (e) 150–106 μm . [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

As a result, the modeling demonstrate that the change in polymer mass ratio (thus the layer thickness) resulted in distinct physicochemical properties (i.e. constant characteristic of diffusion, drug partition coefficient, transition of the mass transport phenomena) of particles arising from their different degradation rates, thus altering the drug release kinetics and profiles.

Particles of various sizes. An increasing drug release rate with decreasing particle size was observed. Surprisingly, the

phenomenon observed by Klose et al.,²¹ who reported that autocatalytic effects compensated for the increased diffusion pathway lengths of drug, resulting in the similar release rates of particles with various sizes, was not seen in the present investigated system. To better understand the drug release mechanism, the degradation behavior of the polymer within the triple-layered microparticles and the theoretical model of drug release profile were investigated.

From Table II, the PLLA degradation rate increased with increasing microparticle size as a result of autocatalytic

FIGURE 7. Cumulative ibuprofen release from triple-layered PLGA/PLLA/EVA microparticles of various sizes during stage 2. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

effect. This result could be attributed to the rapid diffusion of acidic degradation products into the surrounding bulk fluid for the smaller microparticles. In addition, as a result of higher concentration gradients, basic ions from the phosphate buffer could diffuse into the microparticles more easily with decreasing particle dimension, thus neutralizing the generated acids.

As shown in the modeling results, a shorter diffusion pathway can be achieved with decreasing particle size, thus increasing the constant characteristic of diffusion. In contrast, the end of stage 1 (t_a) for each of the investigated size range was at around day 8. Although the decreased polymer degradation rate with decreasing device dimension would decrease the drug diffusion coefficient in the membrane, the decreased particle size (decreased diffusion pathway length) was shown to compensate for this effect, achieving similar diffusion rates. Time taken for drug molecules to diffuse and establish a concentration gradient across the membrane with easy drug partitioning (after certain extent of degradation) for various particle sizes would be the same (i.e. at around 8 days). As such, the interplay between the extent of degradation and layer dimensions was substantiated to determine t_a .

Denser structure of slowly degrading PLLA would hinder the partitioning of drug from the core into the PLLA layer. In spite of this, the drug release from the smaller-sized triple-layered microparticles still proceeded relatively faster at stage 2 due to a decreased diffusion pathway length, as shown in Figure 7. From the modeling results, it is suggested that the change in particle sizes greatly affected the diffusion pathway length, thus varying the drug release rates, rather than achieving partition- and degradation-controlled release in the investigated system (size range 10–150 µm in diameter).

CONCLUSIONS

Appropriate release model for the triple-layered microparticles of different layer thicknesses and particle sizes, where ibuprofen was localized in the core, has been proposed in this article. This theoretical model demonstrated good agreements with experimentally measured data. The triple-layered microparticles released its drug through initial sim-

ple diffusion followed by a release through a rate-limiting outer layer (membrane) that was undergoing hydrolytic degradation. Three parameters, including constant characteristic of diffusion, transition time point between two drug release mechanisms and partition coefficient of drug, were determined by the model. These parameters were shown to provide mechanistic insights into a range of drug release profiles of triple-layered microparticles with various device dimensions.

REFERENCES

- Freiberg S, Zhu X. Polymer microspheres for controlled drug release. *Int J Pharm* 2004;282:1–18.
- Lu Y, Chen SC. Micro and nano-fabrication of biodegradable polymers for drug delivery. *Adv Drug Deliv Rev* 2004;56:1621–1633.
- Lee TH, Wang JJ, Wang CH. Double-walled microspheres for the sustained release of a highly water soluble drug: Characterization and irradiation studies. *J Control Release* 2002;83:437–452.
- Shi M, Yang YY, Chaw CS, Goh SH, Mochhala SM, Ng S, Heller J. Double walled POE/PLGA microspheres: Encapsulation of water-soluble and water-insoluble proteins and their release properties. *J Control Release* 2003;89:167–177.
- Kokai LE, Tan H, Jhunjhunwala S, Little SR, Frank JW, Marra KG. Protein bioactivity and polymer orientation is affected by stabilizer incorporation for double-walled microspheres. *J Control Release* 2010;141:168–176.
- Lee WL, Hong M, Widjaja E, Loo SCJ. Formation and degradation of biodegradable triple-layered microparticles. *Macromol Rapid Commun* 2010;31:1193–1200.
- Lee WL, Loei C, Widjaja E, Loo SCJ. Altering the drug release profiles of double-layered ternary-phase microparticles. *J Control Release* 2011;151:229–238.
- Tan HX, Ye J. Surface morphology and in vitro release performance of double-walled PLLA/PLGA microspheres entrapping a highly water-soluble drug. *Appl Surf Sci* 2007;255:353–356.
- Matsumoto A, Matsukawa Y, Suzuki T, Yoshino H. Drug release characteristics of multi-reservoir type microspheres with poly(DL-lactide-co-glycolide) and poly(DL-lactide). *J Control Release* 2005;106:172–180.
- Lee WL, Widjaja E, Loo SCJ. One-step fabrication of triple-layered polymeric microparticles with layer localization of drugs as a novel drug-delivery system. *Small* 2010;6:1003–1011.
- Grassi M, Grassi G. Mathematical modelling and controlled drug delivery: Matrix systems. *Curr Drug Deliv* 2005;2:97–116.
- Siepmann J, Peppas N. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). *Adv Drug Deliv Rev* 2001;48:139–157.
- Lamberti G, Galdi I, Barba AA. Controlled release from hydrogel-based solid matrices. A model accounting for water up-take, swelling and erosion. *Int J Pharm* 2011.
- Siepmann J, Kranz H, Bodmeier R, Peppas N. HPMC-matrices for controlled drug delivery: A new model combining diffusion, swelling, and dissolution mechanisms and predicting the release kinetics. *Pharm Res* 1999;16:1748–1756.
- Siepmann J, Gopferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. *Adv Drug Delivery Rev* 2001;48:229–247.
- Lao LL, Peppas NA, Boey FYC, Venkatraman SS. Modeling of drug release from bulk-degrading polymers. *Int J Pharm* 2011;418:28–41.
- Siepmann J, Faisant N, Akiki J, Richard J, Benoit JP. Effect of the size of biodegradable microparticles on drug release: Experiment and theory. *J Control Release* 2004;96:123–134.
- Crank J. *The Mathematics of Diffusion*. Oxford University Press; 1983.
- Zhou Y, Chu JS, Li JX, Wu XY. Theoretical analysis of release kinetics of coated tablets containing constant and non-constant drug reservoirs. *Int J Pharm* 2010;385:98–103.
- Iordanskii AL, Feldstein MM, Markin VS, Hadgraft J, Plate NA. Modeling of the drug delivery from a hydrophilic transdermal

- therapeutic system across polymer membrane. *Eur J Pharm Biopharm* 2000;49:287–293.
21. Klose D, Siepmann F, Elkharraz K, Siepmann J. PLGA-based drug delivery systems: Importance of the type of drug and device geometry. *Int J Pharm* 2008;354:95–103.
 22. Charlier A, Leclerc B, Couarraze G. Release of mifepristone from biodegradable matrices: Experimental and theoretical evaluations. *Int J Pharm* 2000;200:115–120.
 23. Tan EC, Lin RY, Wang CH. Fabrication of double-walled microspheres for the sustained release of doxorubicin. *J Colloid Interface Sci* 2005;291:135–143.
 24. Lee WL, Foo WL, Widjaja E, Loo SCJ. Manipulation of process parameters to achieve different ternary-phase microparticle configurations. *Acta Biomater* 2010;6:1342–1352.
 25. Vergnaud JM. *Controlled Drug Release of Oral Dosage Forms*. CRC; 1993.
 26. Langer RS, Wise DL. *Medical Applications of Controlled Release*. Boca Raton, FL: CRC Press; 1984.
 27. Baker RW, Lonsdale HK. *Controlled Release: Mechanisms and Rates*. New York, NY: Plenum Press; 1974. p 15–71.
 28. Baker RW. *Controlled Release of Biologically Active Agents*. John Wiley & Sons; 1987.
 29. Arifin DY, Lee LY, Wang CH. Mathematical modeling and simulation of drug release from microspheres: Implications to drug delivery systems. *Adv Drug Deliv Rev* 2006;58:1274–1325.
 30. Kenley RA, Lee MO, Mahoney TR, Sanders LM. Poly(lactide-co-glycolide) decomposition kinetics in vivo and in vitro. *Macromolecules* 1987;20:2398–2403.
 31. Frank A, Rath SK, Venkatraman SS. Controlled release from bioerodible polymers: Effect of drug type and polymer composition. *J Control Release* 2005;102:333–344.
 32. Tiwari SK, Tzezana R, Zussman E, Venkatraman SS. Optimizing partition-controlled drug release from electrospun core-shell fibers. *Int J Pharm* 2010;392:209–217.
 33. Raghuvanshi RS, Singh M, Talwar GP. Biodegradable delivery system for single step immunization with tetanus toxoid. *Int J Pharm* 1993;93:1–5.
 34. Klose D, Siepmann F, Elkharraz K, Krenzlin S, Siepmann J. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. *Int J Pharm* 2006;314:198–206.

Author Proof

AQ1: Kindly check whether the short title is OK as given.

AQ2: Please confirm that all author names are OK and are set with first name first, surname last.

AQ3: Please confirm whether the color figures should be reproduced in color or black and white in the print version. If the color figures must be reproduced in color in the print version, please fill the color charge form immediately and return to Production Editor. Or else, the color figures for your article will appear in color in the online version only.

Author Proof